Tonghua Dongbao Pharmaceutical Co Ltd (600867) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tonghua Dongbao Pharmaceutical Co Ltd (600867) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥62.99 Million ≈ $9.22 Million USD) by net assets (CN¥7.14 Billion ≈ $1.04 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tonghua Dongbao Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 600867 total debt and obligations for a breakdown of total debt and financial obligations.
Tonghua Dongbao Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tonghua Dongbao Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acer Incorporated
F:AC5G
|
0.017x |
|
Artisan Partners Asset Management Inc
NYSE:APAM
|
0.052x |
|
Kinik Co
TW:1560
|
0.048x |
|
Thule Group AB
ST:THULE
|
0.007x |
|
Hytera Communications Corp Ltd
SHE:002583
|
-0.085x |
|
AMP Ltd
AU:AMP
|
-0.316x |
|
Highwealth Construction Corp
TW:2542
|
-0.019x |
|
Ero Copper Corp
TO:ERO
|
0.143x |
Annual Cash Flow Conversion Efficiency for Tonghua Dongbao Pharmaceutical Co Ltd (1998–2024)
The table below shows the annual cash flow conversion efficiency of Tonghua Dongbao Pharmaceutical Co Ltd from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Tonghua Dongbao Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥6.40 Billion ≈ $936.58 Million |
CN¥459.74 Million ≈ $67.27 Million |
0.072x | -39.83% |
| 2023-12-31 | CN¥7.22 Billion ≈ $1.06 Billion |
CN¥861.52 Million ≈ $126.07 Million |
0.119x | -9.40% |
| 2022-12-31 | CN¥6.55 Billion ≈ $958.41 Million |
CN¥863.09 Million ≈ $126.30 Million |
0.132x | -27.75% |
| 2021-12-31 | CN¥6.22 Billion ≈ $910.21 Million |
CN¥1.13 Billion ≈ $166.02 Million |
0.182x | -14.95% |
| 2020-12-31 | CN¥5.56 Billion ≈ $813.52 Million |
CN¥1.19 Billion ≈ $174.47 Million |
0.214x | -6.77% |
| 2019-12-31 | CN¥5.01 Billion ≈ $732.95 Million |
CN¥1.15 Billion ≈ $168.60 Million |
0.230x | +24.18% |
| 2018-12-31 | CN¥4.73 Billion ≈ $692.77 Million |
CN¥876.94 Million ≈ $128.32 Million |
0.185x | -12.56% |
| 2017-12-31 | CN¥4.54 Billion ≈ $663.97 Million |
CN¥961.19 Million ≈ $140.65 Million |
0.212x | +15.15% |
| 2016-12-31 | CN¥3.95 Billion ≈ $577.31 Million |
CN¥725.76 Million ≈ $106.20 Million |
0.184x | +54.81% |
| 2015-12-31 | CN¥2.48 Billion ≈ $362.76 Million |
CN¥294.58 Million ≈ $43.11 Million |
0.119x | +24.69% |
| 2014-12-31 | CN¥2.16 Billion ≈ $316.15 Million |
CN¥205.89 Million ≈ $30.13 Million |
0.095x | -13.08% |
| 2013-12-31 | CN¥2.02 Billion ≈ $295.04 Million |
CN¥221.06 Million ≈ $32.35 Million |
0.110x | +12.35% |
| 2012-12-31 | CN¥1.99 Billion ≈ $291.37 Million |
CN¥194.32 Million ≈ $28.44 Million |
0.098x | +468.21% |
| 2011-12-31 | CN¥2.08 Billion ≈ $304.07 Million |
CN¥-55.07 Million ≈ $-8.06 Million |
-0.027x | -128.63% |
| 2010-12-31 | CN¥1.73 Billion ≈ $253.53 Million |
CN¥160.40 Million ≈ $23.47 Million |
0.093x | -9.39% |
| 2009-12-31 | CN¥1.63 Billion ≈ $238.04 Million |
CN¥166.20 Million ≈ $24.32 Million |
0.102x | +58.67% |
| 2008-12-31 | CN¥1.43 Billion ≈ $209.78 Million |
CN¥92.31 Million ≈ $13.51 Million |
0.064x | -18.33% |
| 2007-12-31 | CN¥1.53 Billion ≈ $224.47 Million |
CN¥120.94 Million ≈ $17.70 Million |
0.079x | -36.33% |
| 2006-12-31 | CN¥1.28 Billion ≈ $186.72 Million |
CN¥158.00 Million ≈ $23.12 Million |
0.124x | +80.01% |
| 2005-12-31 | CN¥1.34 Billion ≈ $196.19 Million |
CN¥92.23 Million ≈ $13.50 Million |
0.069x | +592.91% |
| 2004-12-31 | CN¥1.33 Billion ≈ $194.05 Million |
CN¥13.17 Million ≈ $1.93 Million |
0.010x | -69.43% |
| 2003-12-31 | CN¥1.40 Billion ≈ $205.04 Million |
CN¥45.51 Million ≈ $6.66 Million |
0.032x | +38.36% |
| 2002-12-31 | CN¥1.36 Billion ≈ $199.45 Million |
CN¥31.99 Million ≈ $4.68 Million |
0.023x | -72.51% |
| 2001-12-31 | CN¥1.38 Billion ≈ $201.72 Million |
CN¥117.73 Million ≈ $17.23 Million |
0.085x | +317.87% |
| 2000-12-31 | CN¥1.43 Billion ≈ $208.52 Million |
CN¥29.12 Million ≈ $4.26 Million |
0.020x | +130.19% |
| 1999-12-31 | CN¥1.40 Billion ≈ $205.54 Million |
CN¥-95.09 Million ≈ $-13.91 Million |
-0.068x | +71.02% |
| 1998-12-31 | CN¥928.90 Million ≈ $135.93 Million |
CN¥-216.98 Million ≈ $-31.75 Million |
-0.234x | -- |
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more